Business Context and Reporting Period
Company: Community West Bancshares (CWBC)
Filing Type: Form 8-K (Current Report)
Date: March 20, 2026
Event: Supplemental disclosures regarding the proposed merger with United Security Bancshares (USB). The Merger Agreement was signed on December 16, 2025. Shareholder meetings for both companies are scheduled for March 30, 2026.
Key Financial Metrics and Transaction Data
This filing provides supplemental financial data and valuation metrics rather than standard quarterly operating results. Key transaction and pro forma figures include:
- Projected Combined Balance Sheet (as of June 30, 2026):
- Total Assets: $4,951 million (CWBC: $3,687M / 75%; USB: $1,264M / 25%)
- Total Loans: $3,533 million (CWBC: $2,546M / 72%; USB: $987M / 28%)
- Total Deposits: $4,225 million (CWBC: $3,125M / 74%; USB: $1,100M / 26%)
- Tangible Common Equity: $455 million (CWBC: $318M / 70%; USB: $137M / 30%)
- Profitability (LTM as of Sept 30, 2025):
- Net Income: $45.3 million combined (CWBC: $33.9M / 75%; USB: $11.4M / 25%)
- 2026 Estimated Earnings: $60.2 million combined (CWBC: $44.6M / 74%; USB: $15.6M / 26%)
- Market Capitalization (as of Dec 15, 2025): $646 million combined (CWBC: $463M; USB: $183M)
- Exchange Ratio: 0.4520x (Pro forma ownership: CWBC 71%, USB 29%)
- Valuation Multiples (USB): 145.3% of Tangible Book Value; 17.0x LTM EPS.
Material Changes and Litigation
Litigation and Demand Letters:
- Two lawsuits challenging the merger were filed in New York Supreme Court on March 4 and March 5, 2026 (Johnson v. United Security Bancshares et al. and Thompson v. United Security Bancshares et al.).
- Additional demand letters have been received alleging disclosure deficiencies in the Joint Proxy Statement/Prospectus.
- Management Response: The companies believe the allegations are without merit but are voluntarily providing supplemental disclosures to avoid delay and distraction.
Supplemental Disclosures:
- Board Process: Clarified that USB and its advisors periodically solicited interest from potential buyers, but no other candidate expressed actionable interest recently other than CWBC.
- Director Continuity: Disclosed that the USB Board viewed the continuity of director positions and Mr. Woods' employment as integral to the transaction's success. Detailed employment terms for Mr. Woods were negotiated after the definitive agreement was substantially negotiated to address conflict of interest concerns.
- Valuation Analysis: Added detailed tables for Comparable Company Analysis, Precedent Transactions (Nationwide and Regional), and Discounted Cash Flow (DCF) assumptions used by financial advisors Janney and Piper Sandler.
Guidance, Outlook, and Risks
Outlook and Accretion:
- EPS Accretion: The merger is projected to be accretive to CWBC earnings per share by 10.2% (closing), 19.1% (2026E), 18.0% (2027E), 16.4% (2028E), and 16.4% (2029E).
- Tangible Book Value (TBV) Dilution: The merger is projected to be dilutive to TBV per share initially, ranging from -9.5% at closing to -0.2% in 2029, before becoming accretive (2.2%) in 2030.
Risks and Contingencies:
- Failure of shareholders to approve the merger at the March 30, 2026 meetings.
- Integration delays, increased costs, or failure to realize anticipated benefits.
- Diversion of management attention and potential loss of key employees.
- Changes in tax legislation or global economic conditions.
- Potential for additional lawsuits or demands regarding the merger.
Investor Verification Checklist
- Verify the status of the two pending lawsuits in New York Supreme Court and any potential for injunctive relief delaying the March 30 shareholder vote.
- Review the "Joint Proxy Statement/Prospectus" (effective Feb 24, 2026) in conjunction with these supplemental disclosures to understand the full context of the board's decision-making process.
- Confirm the specific terms of the employment agreements for Mr. Woods and other directors to assess potential conflicts of interest.
- Monitor the shareholder vote results on March 30, 2026, as the transaction is contingent upon approval by both CWBC and USB shareholders.
- Assess the long-term impact of the projected TBV dilution (up to 9.5% initially) against the EPS accretion benefits.